Archives

Pipeline

Fifteen drugs and devices have entered a new trial phase this week

January 15, 2018

Company Drug/Device Medical Condition Status
Chimerix brincidofovir adenovirus infection related to pediatric transplant Phase I trials initiated in 141 subjects in the U.S. and Europe
Oncolix Prolanta advanced ovarian cancer Phase I trials initiated
Immix Biopharma IMX-110 advanced Solid Tumors Phase I/IIa trials planned
Aptevo Therapeutics otlertuzumab peripheral T-cell lymphoma Phase II trials initiated enrolling 24 subjects
Novaliq NOV03 dry eye disease Phase II trials initiated
Akcea Therapeutics AKCEA-APOCIII-LRx hypertriglyceridemia, established cardiovascular disease Phase IIb trials initiated
CymaBay Therapeutics seladelpar primary biliary cholangitis Phase II/III trials initiated
Minoryx Therapeutics MIN-102 adrenomyeloneuropathy Phase II/III trials initiated globally
Semnur Pharmaceuticals SP-102 lumbar radicular pain/sciatica Phase III trials initiated enrolling 400 subjects in the U.S.
Semnur Pharmaceuticals SP-102 lumbar radicular pain/sciatica Fast Track designation granted by the FDA
Avadel Pharma FT 218 narcolepsy Orphan Drug designation granted by the FDA
Spruce Biosciences SPR001 congenital adrenal hyperplasia Orphan Drug designation granted by the EMA
AbbVie upadacitinib (ABT-494) moderate to severe atopic dermatitis Breakthrough Therapy designation granted by the FDA
Global Blood Therapeutics voxelotor sickle cell disease Breakthrough Therapy designation granted by the FDA
Amgen Xgeva (denosumab) prevention of skeletal-related events in patients with multiple myeloma FDA expanded approval